Table of Contents As filed with the U.S. Securities and Exchange Commission on February 17, 2026. Registration No. 333-290086 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OPTIMI HEALTH CORP. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organi ...

Core Viewpoint - MindMed is gaining significant investor attention as it advances its clinical programs, with shares valued at approximately $1.4 billion and an 83.5% increase over the past 52 weeks, indicating strong momentum heading into 2025 [1][7]. Company Overview - MindMed, based in New York, is a late-stage clinical biopharmaceutical company focused on innovative treatments for brain health disorders, particularly through psychedelic-inspired therapies [3][5]. - The company's lead asset, MM120, is currently in Phase 3 trials for generalized anxiety disorder, addressing a condition that has been underserved by existing therapies [3][5]. Clinical Pipeline - MindMed is developing MM402, an MDMA-inspired compound aimed at treating autism spectrum disorder by targeting core symptoms [2]. - The company has a robust pipeline focused on complex mental health challenges, with MM120 showing promising results in clinical trials [2][12]. Financial Performance - In Q3 2025, MindMed reported a loss of $0.78 per share, wider than the previous year's loss of $0.27 and below Wall Street's estimate of $0.52, reflecting a focus on investment and development rather than immediate revenue generation [9][10]. - Research and development costs increased significantly from $17.2 million in Q3 2024 to $31 million, driven by expenses related to the MM120 program and higher staffing costs [10]. - As of September 30, 2025, the company had cash and investments totaling $209.1 million, sufficient to fund operations through 2028, further bolstered by a public offering that raised $258.9 million [11]. Market Sentiment - Analysts have taken a bullish stance on MindMed, with Jones Trading initiating coverage and setting a price target of $61, suggesting a potential upside of over 354% from current levels [4][16]. - The consensus rating for MindMed is "Strong Buy," with 10 out of 13 analysts recommending a "Strong Buy," indicating strong market confidence in the company's future prospects [18]. Clinical Data and Future Outlook - MindMed's MM120 has received FDA Breakthrough Therapy Designation, with Phase 2b data showing a 65% response rate and a 48% remission rate at 12 weeks, highlighting its potential efficacy [12]. - Looking ahead, the company is preparing for a pivotal 2026 with three Phase 3 readouts planned for anxiety and depression, positioning itself for significant advancements in the mental health treatment landscape [13].